Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Rhea-AI Summary

Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel payload antibody drug conjugates (ADCs), has announced its participation in the upcoming LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar. President and CEO Abizer Gaslightwala will present and discuss recent corporate developments on Thursday, May 29, 2025, at 2:20 PM ET. The presentation will be accessible through a webcast, with registration available for interested participants.

Live webcast on Thursday, May 29th at 2:20 PM ET

BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025 at 2:00 PM ET.

Conference Details:

Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar 
Date/Time: Thursday, May 29^th at 2:20 PM ET 
Presenter: Abizer Gaslightwala, Director, President and CEO
Registration Link: HERE

About Webull Financial

Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome inhibitor designed to disrupt RNA splicing within cancer cells. This splicing inhibition has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com

FAQ

When is Akari Therapeutics (AKTX) presenting at the Webull Corporate Connect Webinar?

Akari Therapeutics will present at the Webull Corporate Connect Webinar on Thursday, May 29, 2025, at 2:20 PM ET.

Who will be presenting for AKTX at the Webull Corporate Connect Webinar?

Abizer Gaslightwala, President and CEO of Akari Therapeutics, will be presenting at the webinar.

What is Akari Therapeutics' (AKTX) main business focus?

Akari Therapeutics is an oncology biotechnology company that develops novel payload antibody drug conjugates (ADCs).

What topics will be covered in AKTX's Webull Corporate Connect presentation?

The presentation will discuss recent corporate events and developments at Akari Therapeutics.